{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:41:05Z","timestamp":1791186065196,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"This study was partly supported by Universiti Sains Malaysia \u2013 Research University Grant (USM-RU)","award":["1001\/PPSP\/812070"],"award-info":[{"award-number":["1001\/PPSP\/812070"]}]},{"name":"Fundamental Research Grant Scheme (FRGS)","award":["203\/PPSP\/6171104"],"award-info":[{"award-number":["203\/PPSP\/6171104"]}]}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.leukres.2013.12.025","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T18:46:02Z","timestamp":1389033962000},"page":"454-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients\u2014Frequency and clinical outcome"],"prefix":"10.1016","volume":"38","author":[{"given":"Marjanu Hikmah","family":"Elias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Aziz","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husin","family":"Azlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Rosline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goh Ai","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menon","family":"Padmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Abdul Wahid","family":"Fadilah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Ankathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.12.025_bib0005","first-page":"136","article-title":"Molecular targeted treatment \u2013 new treatment strategy for patients with chronic myeloid leukemia","volume":"52","author":"Usui","year":"2004","journal-title":"Rinsho Byori"},{"key":"10.1016\/j.leukres.2013.12.025_bib0010","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.12.025_bib0015","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2013.12.025_bib0020","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.12.025_bib0025","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.4081\/hr.2012.e23","article-title":"Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients","volume":"4","author":"Elias","year":"2012","journal-title":"Hematol Rep"},{"key":"10.1016\/j.leukres.2013.12.025_bib0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.12.025_bib0035","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.12.025_bib0040","series-title":"Cytogenetics, FISH and molecular testing in hematologic malignancies","first-page":"319","author":"Gorczyca","year":"2008"},{"key":"10.1016\/j.leukres.2013.12.025_bib0045","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.leukres.2013.12.025_bib0050","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.12.025_bib0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2013.12.025_bib0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Rosee","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2013.12.025_bib0065","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.12.025_bib0070","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571","volume":"277","author":"Corbin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.12.025_bib0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2013.12.025_bib0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.12.025_bib0085","series-title":"50th ASH Annual Meeting and Exposition","article-title":"The M351T BCR-ABL kinase mutation is uncommon in asian patients with imatinib-resistant chronic myeloid leukemia: possible relationship with imatinib plasma levels","author":"Ang","year":"2008"},{"key":"10.1016\/j.leukres.2013.12.025_bib0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.894","article-title":"Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent","volume":"27","author":"Kim","year":"2009","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2013.12.025_bib0095","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.12.025_bib0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","article-title":"Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients","volume":"90","author":"Qin","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2013.12.025_bib0105","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.12.025_bib0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-1-15","article-title":"P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia","volume":"1","author":"Cang","year":"2008","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.leukres.2013.12.025_bib0115","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cncr.23355","article-title":"Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations","volume":"112","author":"Lee","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.12.025_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.12.025_bib0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.12.025_bib0130","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613004578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613004578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T16:29:22Z","timestamp":1538929762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613004578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0145212613004578"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.12.025","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients\u2014Frequency and clinical outcome","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}